Last $94.72 USD
Change Today +0.34 / 0.36%
Volume 1.0M
NVS On Other Exchanges
Symbol
Exchange
SIX Swiss Ex
Xetra
New York
OTC US
Mexico
Frankfurt
SIX Swiss Ex
As of 8:04 PM 09/17/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Lichtstrasse 35

Basel, 4056

Switzerland

Phone: 41 61 324 11 11

Fax:

ekturna/Rasilez combined with the diuretic hydrochlorothiazide, sold as Tekturna HCT in the U.S. and Rasilez HCT in the EU, and Tekturna/Rasilez combined with the calcium channel blocker amlodipine, which is sold as Tekamlo in the U.S. and Rasilamlo in the EU. Seebri Breezhaler (glycopyrronium bromide), a once-daily long-acting muscarinic antagonist (LAMA), received its regulatory approvals in 2012. Seebri Breezhaler 44 mcg inhalation powder, hard capsules received approval in the EU as a maintenance bronchodilator treatment to relieve symptoms for adult patients with COPD, and in Japan the MHLW approved Seebri (glycopyrronium) Inhalation Capsules 50 mcg administered through the Breezhaler device as an inhaled maintenance bronchodilator treatment for the relief of various symptoms due to airway obstructive disease in COPD (chronic bronchitis, emphysema). It is approved in approximately 50 countries worldwide. Ultibro Breezhaler (indacaterol/glycopyrronium bromide) is a once-daily fixed-dose combination of the LABA indacaterol and the LAMA glycopyrronium bromide. Ultibro Breezhaler (indacaterol 85 mcg / glycopyrronium 43 mcg), inhalation powder, hard capsules was approved in the EU in 2013 as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD, and in Japan the MHLW approved Ultibro Inhalation Capsules (glycopyrronium 50 mcg/indacaterol 110 mcg), delivered through the Breezhaler inhalation device, for relief of various symptoms due to airway obstruction in COPD (chronic bronchitis, emphysema). Ultibro Breezhaler is the third inhaled COPD product available to patients to be delivered via the Breezhaler inhalation device. Established Medicines Voltaren/Cataflam (diclofenac sodium/potassium/resinate/free acid) is a non-steroidal anti-inflammatory drug (NSAID) for the relief of symptoms in rheumatic diseases, such as rheumatoid arthritis and osteoarthritis, and for various other inflammatory and pain conditions. Voltaren/Cataflam is available in approximately 140 countries. This product, which is subject to generic competition, is marketed by the Pharmaceuticals Division in various dosage forms, including tablets, drops, suppositories, ampoules and topical therapy. In addition, in various countries, the company’s Sandoz Division markets generic versions of the product, its Alcon Division markets Voltaren for ophthalmic indications, and its OTC Division markets low-dose oral forms and the topical therapy of Voltaren as over-the-counter products. Ritalin, Ritalin LA, Focalin and Focalin XR (methylphenidate HCl, methylphenidate HCl extended release, dexmethylphenidate HCl and dexmethylphenidate HCl extended release) are indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and Focalin XR is additionally indicated for adults. Ritalin and Ritalin LA are also indicated for narcolepsy. Ritalin is available in approximately 70 countries. Ritalin LA is available in approximately 30 countries. Focalin comprises the active d-isomer of methylphenidate and therefore requires half the dose of Ritalin. Focalin XR is approved in Switzerland. Focalin and Focalin XR are available in the U.S. Ritalin immediate-release has generic competition in most countries. Reclast/Aclasta (zoledronic acid 5 mg) is the once-yearly bisphosphonate infusion for the treatment of different forms of osteoporosis, and for the treatment of Paget's disease of the bone in men and women. Sold as Reclast in the U.S. and Aclasta in the rest of the world, the product is approved in approximately 100 countries including the U.S., EU member states and Canada, and is the bisphosphonate approved to reduce the incidence of fractures at all three key fracture sites (hip, spine and non-spine) in the treatment of postmenopausal osteoporosis. The Reclast/Aclasta label was expanded in the EU and U.S. to include the reduction in the incidence of clinical fractures after a low trauma hip fracture. Reclast is also approved in the U.S. as a treatment to increase bone mass in men with osteoporosis, the prevention and treatment of glucocorticoid-induced osteoporosis in men and women, as well as for t

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVS:US $94.72 USD +0.34

NVS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $103.84 USD -0.92
Merck & Co Inc $59.88 USD -0.11
Pfizer Inc $30.35 USD +0.30
Roche Holding AG SFr.280.80 CHF +3.30
Procter & Gamble Co/The $84.16 USD +0.08
View Industry Companies
 

Industry Analysis

NVS

Industry Average

Valuation NVS Industry Range
Price/Earnings 25.6x
Price/Sales 3.9x
Price/Book 3.3x
Price/Cash Flow 26.4x
TEV/Sales 3.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-ADR, please visit www.novartis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.